Objective: To evaluate safety of oseltamivir in neonates with significant comorbidities in a level-III neonatal intensive care unit during an outbreak of 2009 H1N1 influenza.
Introduction
Infants are at high risk of serious complications from influenza. [1] [2] [3] [4] [5] [6] Hospitalization rates attributable to influenza average 4.5 per 1000 children under 6 months of age, exceeding rates in high risk adults and the elderly. 2, 7 Unfortunately, protection and treatment are limited in this vulnerable young age group. 8 Current influenza vaccine is not effective in infants under 6 months of age. 9, 10 Two classes of antiviral agents, neuraminidase inhibitors and adamantanes, only are approved for treatment or prophylaxis of influenza in patients older than 1 year in which safety and pharmacokinetics have been studied. [11] [12] [13] Although adamantanes were effective against oseltamivir-resistant seasonal H1N1 influenza circulating during 2008 to 2009, only neuraminidase inhibitors are effective against the majority of 2009 H1N1 influenza, circulating H3N2, and all influenza B strains because of inherent or newly developed drug resistance. 14 In response to the 2009 H1N1 pandemic, the United States Food and Drug Administration issued an Emergency Use Authorization for oseltamivir use in children <12 months of age. 15 This Emergency Use Authorization was terminated on 23 June 2010.
In June and July 2009, an outbreak of 2009 H1N1 influenza affecting 11 neonates occurred in a 35-bed neonatal intensive care unit (NICU) at an urban hospital in Los Angeles. During this emergency situation affecting high-risk neonates, all ill patients with signs of respiratory infection and all exposed infants were given oseltamivir treatment or prophylaxis. We document here the clinical safety and tolerability of oseltamivir use in the treatment and prophylaxis of neonates with influenza illness or exposure.
Methods
Influenza A was detected initially in nasal washes from three neonates with acute respiratory decompensation within a 48-h period using TruFlu (Meridian Bioscience, Cincinnati, OH, USA), a rapid influenza detection test (RIDT) that targets both influenza A and B viral nucleoprotein antigens. Owing to concern for an outbreak, screening with RIDT was performed on all remaining infants in the NICU. Specimens from all ill neonates were sent to the Los Angeles County Department of Public Health for confirmatory testing by reverse transcriptase PCR (RT-PCR) using the sequencing primers and protocol of RT-PCR for 2009 influenza A (H1N1) published by the CDC. 16 In addition, a few ill neonates who tested negative for influenza using RIDT also underwent testing using a multiplex PCR for respiratory viruses (Luminex xTag performed at Viracor Laboratories, Kansas City, MO, USA). Viral testing was performed only at the time of initiating treatment or prophylaxis. Viral cultures were not available for diagnosis.
All exposed neonates were given treatment or prophylaxis dosing of oseltamivir through oral administration as recommended by the CDC following the Emergency Use Authorization of oseltamivir for use for treatment of children <1-year old with 2009 H1N1 influenza by the Food and Drug Administration in May 2009. 17 Dosing was based on infant age and not modified by weight. However, dosing interval was extended to every 48 h in patients with renal insufficiency as determined by the treating neonatologist. Oseltamivir serum levels were not measured.
At the start of oseltamivir administration, infectious disease specialists met with neonatology staff to review potential clinical and laboratory adverse effects of oseltamivir including gastrointestinal, dermatologic, neurologic, hematologic and renal effects and death. Physical examinations were performed daily on each patient by staff neonatologists. All hospitalized infants were continuously monitored in the NICU by nurses during the course of oseltamivir. Parents of patients who were discharged during oseltamivir prophylaxis were called to ask about any adverse reactions. Laboratory studies were performed on days 5 and 10 after initiation of oseltamivir. These included white blood cell count, hemoglobin, platelet count, serum creatinine, aspartate aminotransferase, alanine aminotransferase, bilirubin and alkaline phosphatase.
For all neonates who received oseltamivir treatment or prophylaxis, medical charts were reviewed for fever, cough, increased secretions, apnea, bradycardia, desaturation, increased oxygen requirement, intubation or change in ventilator settings, vomiting, diarrhea and clinical change that could be compatible with influenza illness. Adverse events within 30 days of oseltamivir administration were assessed from the chart. The t-test was used to evaluate for statistical differences in laboratory values. All tests were two-tailed, and P<0.05 was considered significant. This retrospective study was approved by the Institutional Review Board at the Childrens Hospital Los Angeles. Parental consent was not required.
Results

Patient characteristics
The 2009 H1N1 influenza outbreak occurred in the NICU of an urban children's hospital in June and July 2009, during a time of widespread influenza activity in the community. This NICU is a 35-bed level III nursery that receives neonates transferred from outside hospitals for high-acuity or specialized surgical care. An investigation by the hospital and the local Department of Public Health revealed that the likely source of the outbreak was an ill family member. Because of the outbreak situation and exposure of high-risk neonates in multi-bed rooms, all ill and influenza screen-positive infants were treated with oseltamivir and all exposed infants hospitalized in the NICU were given prophylaxis with oseltamivir as a control measure. In addition, control measures included isolation and cohorting of ill patients, increased emphasis on hand hygiene, combined droplet and contact precautions, visitor restriction, monitoring against ill health care personnel and closure of the NICU to new admissions.
Characteristics and primary diagnoses of neonates who received treatment and prophylaxis with oseltamivir are displayed in Tables 1 and 2 , respectively. Median gestational age was 36.8 weeks. A total of 14 (43.8%) infants were born pre-term at less than 36 weeks' gestation. Median age at the time of oseltamivir initiation was 1.4 months; 15 (46.9%) infants were younger than 30 days of age. Median corrected gestational age was 41.7 weeks (range, 32.3 to 86.4 weeks). Birth weights ranged from 450 to 4,375 g (median, 2311 grams). At initiation of oseltamivir, median weight was 3083 g. In all, 15, 5 and 1 infants weighed less than 3000, 2000 and 1000 g, respectively.
In total, 11 neonates received treatment and 21 received prophylaxis with oseltamivir. Of the 11 treated patients, 6 presented with clinical signs consistent with influenza illness (Table 1) . Nasal wash specimens were tested for influenza using RIDT, RT-PCR and/or Luminex with results shown in Table 1 . Testing by RT-PCR of influenza A-positive specimens established that the outbreak was caused by 2009 H1N1 influenza virus. Of the 6 ill patients, only 3 were confirmed to have influenza by RT-PCR. In all, 4 patients without clinical findings were treated following a positive RIDT. Only 1 of these 4 patients tested positive for influenza by RT-PCR. In addition, 1 infant (patient 11) was treated with oseltamivir after he developed fever and tachypnea on the second day of prophylaxis; however, two consecutive blood cultures grew Enterobacter species. RIDT, RT-PCR and Luminex were negative for influenza virus in this patient. All 21 patients who received oseltamivir prophylaxis had nasal wash specimens that were negative for influenza by RIDT at initiation of prophylaxis; 13 who underwent testing by RT-PCR were confirmed negative.
All infants undergoing influenza treatment received oseltamivir as inpatients in the NICU. In the prophylaxis group, 19 completed the antiviral course as inpatients; 2 infants were discharged during their 10-day course.
Oseltamivir dosing and administration Between 12 and 25 mg twice daily for treatment and once daily for prophylaxis were given based on age and administered orally or through a nasogastric tube. 18 Three patients in the prophylaxis group were given every 48 h dosing because of renal insufficiency (creatinine 1.4 to 3.4 mg dl À1 ). Dosing ranged between 2 and 15 mg kg À1 per dose (mean 5.5 mg kg À1 per dose) for all patients. At the initiation of their oseltamivir course, 13 (40.6%) infants were not receiving feeds or other medications by mouth (nil per os). This includes five who had been nil per os since birth secondary to gastroschisis in silo, concurrent extracorporal membrane oxygenation, possible gastrointestinal anatomic anomaly and prostaglandin E administration. A total of 8 were previously fed, but nil per os during at least a part of their oseltamivir course due to necrotizing enterocolitis or recent bowel surgery, concurrent extracorporal membrane oxygenation, feeding intolerance and microaspiration. In total, 10 infants were receiving partial feeds and 9 patients were receiving full feeds during their antiviral course. The neonates received oseltamivir concomitantly with up to 23 other medications (median, six medications) including antibiotics (n ¼ 22), gastrointestinal motility or anti-reflux medications (n ¼ 16), diuretic or antihypertensive (n ¼ 12), systemic steroids (n ¼ 7), muscle relaxant (n ¼ 7), nutritional or hormonal supplement (n ¼ 7), antifungal (n ¼ 6), anti-seizure medication (n ¼ 5), anticoagulant or coagulant factors (n ¼ 5) and cardiac medications (n ¼ 2). Only one patient was not on any additional medications.
Adverse clinical effects
Adverse events that occurred within 30 days of oseltamivir administration are displayed in Tables 1 and 2 . Rash developed in two infants while receiving oseltamivir. One (patient 2) presented with an erythematous rash on bilateral extremities on day 5 of treatment. The rash lasted 2 days and resolved with diphenhydramine therapy; antiviral treatment was completed without interruption. A second (patient 27) developed an erythematous papular rash appearing only on the face on day 7 of prophylaxis. The rash resolved without intervention within 2 days; oseltamivir was continued uninterrupted. Two patients experienced gastrointestinal symptoms while receiving oseltamivir. One (patient 14) had non-bloody loose stools starting on day 2 of prophylaxis and lasted 48 h. The second infant (patient 31) had one episode of bilious emesis on day 5. Neither had underlying gastrointestinal abnormalities and both were on full feeds throughout the entire course. Each completed their 10-day course of oseltamivir without interruption.
An important concern regarding using oseltamivir in neonates is central nervous system toxicity. Our neonates were observed for changes in tone, changes in neurologic examination and seizures. No clinical neurologic signs were observed in any infant during or up to 4 weeks after oseltamivir for a 5-day treatment or 10-day prophylaxis course at recommended doses.
Three deaths occurred in the cohort of patients who received oseltamivir. One infant (patient 1) who received oseltamivir treatment for influenza infection died 2 months after completing treatment. Death was due to complications of congenital heart disease and recurrent chylothorax and not associated with influenza or oseltamivir treatment. One infant (patient 20) died on day 10 of prophylaxis secondary to post-surgical complications with hemoperitoneum and abdominal compartment syndrome; he was receiving anticoagulation while on extracorporal membrane oxygenation. The complications began before the initiation of oseltamivir. A third neonate (patient no. 24) died from disseminated tuberculosis 12 days after receiving only one dose oseltamivir prophylaxis.
Adverse laboratory effects
White blood cell count, hemoglobin, platelet count, serum creatinine, aspartate aminotransferase, alanine aminotransferase, bilirubin and alkaline phosphatase were measured before oseltamivir and on approximately day 5 and 10 after initiation of the antiviral. Statistical evaluation of both treatment and prophylaxis groups showed that there were no significant differences in any of these laboratory studies at day 5 or 10 from baseline. Individual analysis of patients showed that in the 11 neonates who received twice daily dosing of oseltamivir, 3 had abnormal aspartate aminotransferase and alanine aminotransferase associated with a rise of 67 to 182 U l À1 and 55 to 96 U l À1 , respectively, at the end of 5 days. Two (patients 2 and 4) returned to baseline within 5 days of completing therapy; one (patient 1) returned to baseline 14 days after stopping therapy, but this patient had pre-existing liver disease associated with Alagille syndrome. Among the 21 patients who received prophylaxis dosing, only 1 (patient 18) experienced a rise in aspartate aminotransferase, alanine aminotransferase and indirect and direct bilirubin that coincided with surgical complications of hemoperitoneum and abdominal compartment syndrome. One additional infant (patient 24) in the prophylaxis group had a rise in direct bilirubin of 7.9 mg dl À1 without changes in transaminases after a single dose of oseltamivir (4.3 mg kg À1 per dose). Bilirubin continued to rise in this patient, however, after discontinuation of oseltamivir until the infant succumbed to disseminated tuberculosis. There was no association between occurrence of an adverse event and the received dose by weight of oseltamivir (P ¼ 0.24).
Treatment and prophylaxis outcome
Each ill infant with novel H1N1 influenza infection (Table 1) completed a 5-day treatment course of oseltamivir. Four influenza infants began antiviral treatment with oseltamivir within 2 days of becoming ill and showed resolution of clinical findings within 24 h. Two infants were ill for more than 48 h before initiation of oseltamivir; their clinical findings did not improve until 3 to 4 days after treatment began. Four infants without clinical findings who were treated because of positive influenza testing results remained clinically stable. The neonate with Enterobacter species bacteremia who received oseltamivir treatment dosing stabilized after initiation of antibiotics and removal of the infected double lumen femoral venous catheter. Viral testing was not repeated after completion of oseltamivir; however, recurrence of illness or new clinical signs of influenza infection were not observed in any patient after treatment with oseltamivir.
In the prophylaxis group, 17 completed a 10-day oseltamivir course. One completed a 9-day course because of pharmacy error. Two patients were discharged before completion of prophylaxis. One did not fill the oseltamivir prescription upon hospital discharge after the first dose; the family reported that the infant remained well 4 weeks after hospital discharge. Another was discharged after three doses and attempts to contact the family for follow-up were unsuccessful. Prophylaxis was intentionally stopped in only one patient after the first dose because of concern for increasing bilirubin as discussed above. None of the 21 patients who received antiviral prophylaxis with oseltamivir developed clinical signs of influenza infection.
Discussion
Influenza infection leads to severe mortality and morbidity in children under 1 year of age. [1] [2] [3] [4] [5] [6] Availability of treatment and prophylaxis for this age group is desirable, but investigations in infants are limited because an animal study showed mortality in infant rats that received extremely high doses of oseltamivir. 19 Because of the elevated rates of complications from influenza in young infants, physicians in Japan have continued to prescribe oseltamivir in children <1 year of age. One study reported a retrospective review of 103 consecutive infants younger than 1 year of age (mean 7.5 months) treated with oseltamivir for influenza at two hospitals. 20 By follow-up chart review and telephone interviews or letters, none of the infants developed encephalopathy or death. A second study compared oseltamivir treatment of 47 infants 1 to 11 months of age to older children with and without treatment. The treated infants had a similar duration of fever to the treated older children and a significantly shorter duration of illness compared with the untreated older children (P<0.001). 21 A simultaneous control group of infants of the same age was not studied. One treated infant developed diarrhea. There were no other adverse events in the group of treated infants. These reports suggest that oseltamivir use is safe at least in infants down to 1 month of age.
A study by the NIAID Collaborative Antiviral Study Group compared the safety of oseltamivir with adamantanes in children <12 months of age by a retrospective chart review at 15 academic medical centers between 2000 and 2006. 22 There were no significant differences in the occurrence of adverse neurologic events during therapy with 115 infants treated with oseltamivir versus 65 infants treated with the adamantanes. Approximately 10% of the infants in the oseltamivir group were pre-term and 50% had abnormal neonatal courses. Another recent retrospective report found 39% of 157 infants (mean age, 6.3 months) admitted to a major German teaching hospital experienced gastrointestinal effects during oseltamivir treatment; 90% were healthy infants. 23 Our study adds to the literature by reviewing the safety and tolerability of oseltamivir administration specifically in neonates with significant comorbid conditions. Most importantly, there were no adverse neurologic manifestations or mortality associated with oseltamivir use despite their young age and comorbidities. Mild rash, diarrhea and bilious emesis occurred in four infants during their oseltamivir course. The association of these findings with oseltamivir usage cannot be determined with certainty, but all events resolved without discontinuing the oseltamivir course. Laboratory studies monitored for hematologic, renal and hepatic function did not show significant adverse events during oseltamivir administration. The antiviral was intentionally stopped after the first dose in only one patient with a rising bilirubin; however, disseminated tuberculosis shown at autopsy was more likely the cause of this patient's liver failure than the antiviral. Overall, oseltamivir was well tolerated in our neonates as young as 32 weeks' corrected gestation and as small as 775 g with multiple complicated diagnoses.
Oseltamivir prophylaxis appeared to protect neonates from development of influenza infection in our small cohort of patients during the outbreak situation. However, a control group was not studied because all exposed infants were given prophylaxis. We are unable to evaluate clinical effectiveness of oseltamivir in our cohort of treated neonates, as only three ill patients were confirmed to have influenza by RT-PCR and viral cultures were not performed.
Multiple recent reports have shown that RIDTs have variable sensitivity (10 to 69%) for detecting 2009 H1N1 influenza. 24, 18, 25, 26 Specificity is generally higher at 99 to 100%. The positive predictive value ranges from 73 to 100% in these reports. Interestingly, in our small cohort of patients, eight tested positive for influenza using RIDT. The same specimens sent for confirmatory testing showed positivity in only four by RT-PCR, yielding a positive predictive value of only 50%, much lower than most published studies. These surprising results are in alignment with one recent analysis of clinical specimens submitted to the Nebraska Public Health Laboratory showing overall RIDT specificity of 48% during the 2009 H1N1 outbreak. 27 Confirmation of both negative and positive rapid antigen tests is important for appropriate care of patients and infection control measures.
The limitations of this study are its retrospective nature and small sample size. Our unique situation of a pandemic 2009 H1N1 influenza outbreak in the NICU allowed us to examine the safety of oseltamivir use in very young neonates. Neurologic effects were not observed during or up to 4 weeks after oseltamivir use. However, long-term effects were not evaluated. Pharmacokinetic studies were not performed in our cohort. The dosing used in our patients was based on age as recommended by the CDC at the time of the outbreak; therefore the mg kg À1 dose varied widely. Although higher doses per kg were not associated with adverse effects in our cohort, further studies are important and necessary to determine optimal dosing in young infants. The Collaborative Antiviral Study Group recently published pharmacokinetic results that suggest an oseltamivir dose of 1 mg kg À1 per dose twice daily in neonates <38 weeks' gestation achieves oseltamivir carboxylate exposures similar to that in older children receiving 3 mg kg À1 per dose twice daily. 28 This provides initial guidance on weight-based dosing in neonates. Given the high vulnerability of young infants to influenza and the presence of multiple strains of influenza only susceptible to neuraminidase inhibitors, prospective studies of oseltamivir in infants under 1 year of age are indicated to further evaluate its safety and efficacy.
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